CLINICAL_TRIALS ClinicalTrials.gov record update

Safety and Efficacy of Orelabrutinib（O） in Combination With Thiotepa（T） in Refractory and Relapsed Primary CNS Lymphoma： A Single-arm, Multicenter Phase Ib/II Study（OT）

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05021770
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:31.345772+00:00
Published At: 2021-08-26T00:00:00+00:00
Record Updated At: 2021-08-26
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Refractory and Relapsed Primary CNS Lymphoma", "PCNSL", "Non Hodgkin Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-08-26"
protocolSection.identificationModule.nctId: "NCT05021770"
protocolSection.identificationModule.officialTitle: "Safety and Efficacy of Orelabrutinib\uff08O\uff09 in Combination With Thiotepa\uff08T\uff09 in Refractory and Relapsed Primary CNS Lymphoma\uff1a A Single-arm, Multicenter Phase Ib/II Study\uff08OT\uff09"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.